TUCSON, Ariz., July 9, 2026 — Critical Path Institute® (C-Path) has awarded a $250,000 research grant to Teresa Sanchez, Ph.D., of Weill Cornell Medicine, to support the development of a novel therapeutic approach for sepsis-associated neurocognitive dysfunction.Continue reading
The Arizona Bioindustry Association, Inc. (AZBio) and Bio Taiwan execute a Memorandum of Understanding focused on fostering collaborations between organizations in the Arizona and Taiwan life science sectors at the 2026 BIO International Convention in San Diego.
Based in Arizona, Valley Fever Solutions is focused on resolving valley fever and from there, expanding to treat fungal infections more broadly, with a vision to redefine treatment standards in fungal disease.Continue reading
Based in Arizona, ImmunoShield Therapeutics is working to turn the long-promised curative potential of allogeneic cell therapies into a reality, starting with type 1 diabetes.Continue reading
Financing round led by new investor Viking Global Investors with participation from key existing investorsContinue reading
Regulatory milestone underscores opportunity for shared regulatory-science and evidence frameworks to support the next generation of therapies.Continue reading
Aces Diagnostics is focused on solving one of the biggest gaps in infectious disease diagnostics: the lack of accurate testing for Lyme disease.Continue reading
TUCSON, Ariz., June 11, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Milad Alucozai, DrPH, MPH, M.Sc., to its Board of Directors.Continue reading
TUCSON, Ariz., June 10, 2026 — Critical Path Institute® (C-Path) today announced the appointment of Yalonda Howze, J.D., to its Board of Directors. Howze brings nearly two decades of executive leadership and legal experience across the biotechnology and life-science sectors, including her most recent current service as interim chief executive officer and president of Generation Bio.Continue reading
Annual conference returns to Washington, D.C., Sept. 15-16; addresses challenges in establishing a new paradigm for how evidence of efficacy and safety is generated.Continue reading